---
title: "Consun Pharmaceutical Posts Double-Digit Profit Growth and Raises Shareholder Payout"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280564357.md"
description: "Consun Pharmaceutical Group Ltd. reported a 15.2% revenue increase to RMB3.42 billion and an 18.4% rise in net profit to RMB1.08 billion for the year ending December 31, 2025. Basic earnings per share rose to RMB1.27. The company proposed a final dividend of HKD0.40 per share, reflecting confidence in cash generation. Analysts rate the stock as a Buy with a target price of HK$19.50. Consun operates in the pharmaceutical sector, primarily selling prescription drugs in mainland China and other markets."
datetime: "2026-03-26T04:09:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280564357.md)
  - [en](https://longbridge.com/en/news/280564357.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280564357.md)
---

# Consun Pharmaceutical Posts Double-Digit Profit Growth and Raises Shareholder Payout

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from Consun Pharmaceutical Group Ltd. ( (HK:1681) ).

Consun Pharmaceutical Group reported a solid set of annual results for the year ended 31 December 2025, with revenue rising 15.2% to RMB3.42 billion and gross profit improving as cost of sales grew more slowly than topline. Net profit attributable to equity shareholders climbed 18.4% to RMB1.08 billion, while basic earnings per share increased to RMB1.27, underscoring improved operating leverage and profitability.

The company also reduced finance costs significantly and maintained profit growth despite higher distribution and administrative expenses, suggesting continued investment in market expansion and operations. The board proposed a final dividend of HKD0.40 per share, signaling confidence in the group’s cash generation and offering a tangible return to shareholders alongside the earnings growth.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$19.50 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

**More about Consun Pharmaceutical Group Ltd.**

Consun Pharmaceutical Group Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the pharmaceutical industry. The group develops and sells prescription drugs and related pharmaceutical products, generating revenue primarily from the sale of its medicines in mainland China and other markets.

**Average Trading Volume:** 1,749,899

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$13.07B

### Related Stocks

- [01681.HK](https://longbridge.com/en/quote/01681.HK.md)

## Related News & Research

- [United Laboratories Sets June 2026 AGM, Seeks Fresh Share Issuance Mandate](https://longbridge.com/en/news/284525414.md)
- [CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026](https://longbridge.com/en/news/284213122.md)
- [Zealand Pharma Index Exit And New IR Lead Reframe Valuation Story](https://longbridge.com/en/news/284078383.md)
- [BioPhorum acquires Compliance Hub to broaden its specialist pharmaceutical training portfolio](https://longbridge.com/en/news/284386196.md)
- [AbbVie beats earnings estimates, boosts 2026 outlook. What it means for the stock.](https://longbridge.com/en/news/284576830.md)